Two randomized controlled trials and several retrospective studies demonstrated that thalidomide, an oral molecule with immunomodulatory, antiangiogenic, and TNF-suppressing properties, is an effective and safe treatment for adults and children with IBD refractory to conventional therapies.7-9 However, no data on children with VEOIBD have been published. This evidence concerns the gene TNF and inflammatory bowel disease.